+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections

European Journal of Clinical Microbiology & Infectious Diseases 37(1): 141-148

The global emergence of carbapenem-resistant Enterobacteriaceae (CRE) presents a significant clinical concern, prompting the WHO to prioritize CRE as a top priority pathogen in their 2017 global antibiotic-resistant bacteria priority list. Due to the fast-depleting antibiotic arsenal, clinicians are now resorting to using once-abandoned, highly toxic antibiotics such as the polymyxins and aminoglycosides, creating an urgent need for new antibiotics. Drug repurposing, the application of an approved drug for a new therapeutic indication, is deemed a plausible solution to this problem. A total of 1,163 FDA-approved drugs were screened for activity against a clinical carbapenem- and multidrug-resistant E. coli isolate using a single-point 10 μM assay. Hit compounds were then assessed for their suitability for repurposing. The lead candidate was then tested against a panel of clinical CREs, a bactericidal/static determination assay, a time-kill assay and a checkerboard assay to evaluate its suitability for use in combination with Tigecycline against CRE infections. Three drugs were identified. The lead candidate was determined to be Zidovudine (azidothymidine/AZT), an oral anti-viral drug used for HIV treatment. Zidovudine was shown to be the most promising candidate for use in combination with Tigecycline to treat systemic CRE infections. Further experiments should involve the use of animal infection models.

(PDF emailed within 0-6 h: $19.90)

Accession: 060197088

Download citation: RISBibTeXText

PMID: 29019016

DOI: 10.1007/s10096-017-3114-5

Related references

In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. Journal of Global Antimicrobial Resistance 3(4): 278-282, 2016

In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 58(6): 3541-3546, 2014

Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine 95(11): E3126-E3126, 2016

Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. American Journal of Infection Control 40(10): 983-987, 2013

Differences in the rate of carbapenem-resistant enterobacteriaceae colonization or clostridium difficile infection following frontline treatment with tigecycline versus meropenem for intra-abdominal infections. International Journal of Antimicrobial Agents: -, 2018

Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. International Journal of Antimicrobial Agents 49(6): 770-773, 2017

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial ChemoTherapy 60(2): 317-322, 2007

Colistin and Tigecycline Resistance in Carbapenem-Resistant Enterobacteriaceae: Checkmate to Our Last Line Of Defense. Infection Control and Hospital Epidemiology 37(5): 624-625, 2017

Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. Journal of ChemoTherapy 26(5): 276-281, 2015

Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline. Journal of Antimicrobial ChemoTherapy 69(10): 2875-2876, 2015

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. International Journal of Antimicrobial Agents 37(5): 415-419, 2011

Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India. Journal of Clinical and Diagnostic Research 11(3): Dc18-Dc21, 2017

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012. Journal of Global Antimicrobial Resistance 2(3): 179-182, 2014

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagnostic Microbiology and Infectious Disease 83(2): 183-186, 2016

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. Journal of Antimicrobial ChemoTherapy 62(1): 45-55, 2008